Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial.
about
Persistence and compliance with medication management in the treatment of overactive bladderPostmenopausal overactive bladderBotulinum toxin in neurogenic detrusor overactivity.New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment.β3-receptor agonists for overactive bladder--new frontier or more of the same?New therapies in the treatment of overactive bladder.Management of OAB in those over age 65.Efficacy of Transurethral Vesical Deafferentation with Mid-Urethral Sling Operation for Female Mixed Urinary Incontinence: Preliminary Results.Drugs for the overactive bladder: are there differences in persistence and compliance?Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study.Long-term alpha-blockers and anticholinergic combination treatment for men with lower urinary tract symptoms in real-life practice.Individualizing medical treatment of overactive bladder
P2860
Q26765014-C642D02F-2440-45C6-813C-42D555BBC32CQ35157329-1A7B4B05-670D-4464-85CA-F8487D8A26E1Q36313192-A738D2C4-D64F-45FD-A3B4-0F7ADE37260FQ36789948-60E7EC6E-C54B-44F1-A878-5E67AC883259Q37589167-46C7CF19-DCB5-45E5-9644-70E4F3F1197AQ38107167-5E4D91B8-5BF2-4E98-A8FA-E4AD6C8AC0A1Q38124045-09EC2CBC-C02B-4B7C-A2FB-53A1123DF530Q38127155-FF7DED5C-7588-4705-BCDF-C6FCD64AE3A7Q38415170-21DEF0EB-32E9-4D32-B1E9-1A9ED8E50BD1Q42332340-7265172A-68ED-4ABB-9A66-C80E3BD11314Q42690377-A2B805F1-3B8C-4024-9935-E239EF242097Q46351979-F871E7DA-8B49-4521-A398-1928551B04FFQ50914391-605CB843-C6C4-44BD-86BA-D6468DEAF6E0Q53131463-48419AB2-2623-4D69-BCC8-EB55B950CD4DQ57298524-8CB94563-C742-4BF3-952B-3C13ACCBFF15
P2860
Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Symptom change after discontin ...... randomised, multicentre trial.
@en
Symptom change after discontin ...... randomised, multicentre trial.
@nl
type
label
Symptom change after discontin ...... randomised, multicentre trial.
@en
Symptom change after discontin ...... randomised, multicentre trial.
@nl
prefLabel
Symptom change after discontin ...... randomised, multicentre trial.
@en
Symptom change after discontin ...... randomised, multicentre trial.
@nl
P2093
P2860
P1476
Symptom change after discontin ...... randomised, multicentre trial.
@en
P2093
P2860
P304
P356
10.1111/J.1742-1241.2011.02728.X
P577
2011-09-01T00:00:00Z